Psychiatr. pro Praxi, 2008; 9(2): 60-64

Current trends in the treatment of major psychiatric disorders

prof. MUDr. Eva Češková CSc
Psychiatrická klinika LF MU a FN Brno

The concept of major psychiatric disorders is not static and changes with the advances of science. Biomarkers including parameters obtained using brain imaging methods will probably play a more important role in the incoming classification. Major psychiatric disorders, recurrent depression, bipolar and schizophrenic disorders are considered life-long diseases which need long-time treatment. They are more or less consistently connected with functional and structural changes in the brain. The disease and its treatment form a process which has its own dynamics which has to be always considered. Acute treatment has different goals than the maintenance one. The evaluation of treatment efficacy is becoming more and more important. The most important factors for the right treatment choice are the experienced doctor and the patients with their specifics. To them, the clinical picture, individual dispositions to adverse events, somatic diseases, response to previous treatment and experiences and preferences of the ill belong. The final goal is an individualized treatment which is to-day considered optimal.

Keywords: classification, concept of psychiatric disorder, efficacy, side-effects, individualized treatment

Published: April 15, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Češková E. Current trends in the treatment of major psychiatric disorders. Psychiatr. praxi. 2008;9(2):60-64.
Download citation

References

  1. Andreasen NC, Carpenter WT Jr, Kane JM et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry, 2005; 162: 441-449. Go to original source... Go to PubMed...
  2. Bar-Oz B, Einarson T, Einarson A et al. Paroxetine and congenital malformations. Meta-analysis and consideration of potential confounding factors. Clin Ther, 2007; 29: 918-926. Go to original source... Go to PubMed...
  3. Blumberg HP, Krystal JH, Bansal R et al. Age, rapid-cycling, and pharmacotherapy effects on central prefrontal cortex in bipolar disorder: a cross-sectional study. Biol Psychiatry, 2006; 59: 611-618. Go to original source... Go to PubMed...
  4. Cahn W, Hulshoff HE, Lems EB et al. Brain volume changes in first-episode schizophrenia. A 1-year follow-up study. Arch Gen Psychiatry, 2002; 59: 1002-1010. Go to original source... Go to PubMed...
  5. Carney RM, Freedland KE. Does treating depression improve survival after acute coronary syndrome? Br J Psychiatry, 2007; 190: 467-468. Go to original source... Go to PubMed...
  6. Češková E. Schizofrenie a její léčba. 2. vydání. Praha: Jessenius Maxdorf, 2007; 104.
  7. Davis JM. Overview: maintenance therapy in psychiatry: I. Schizophrenia. Am J Psychiatry 1975; 132: 1237-1245. Go to original source... Go to PubMed...
  8. Demyttenaere K. Risk factors and predictors of compliance in depression. Eur. Neuropsychopharmacology, 2003; 13: 69-75. Go to original source... Go to PubMed...
  9. Dunner DL, Blier P, Keller MB et al. Preventing recurrent depression: Long-term treatment for major depressive disorder. J Clin Psychiatry, 2007; 68: 619-630. Go to original source... Go to PubMed...
  10. Fava M, Derme MJ, Balestrieri M et al. Management of depression relapse: re-initiation of duloxetine treatment of dose increase. J Psychiat Res, 2006; 40: 328-336. Go to original source... Go to PubMed...
  11. Fleischhacker WW, Oehl MA, Hummer M. Factors influencing compliance in schizophrenia patients. J Clin Psychiatry, 2003; 64: suppl. 16: 10-13.
  12. Grof P. Selecting effective long-term treatment for bipolar patients: monotherapy and combinations. J Clin Psychiatry, 2005; 64: 53-61.
  13. Hu XH, Bull SA, Hunkeler et al. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry, 2004; 65: 959-965. Go to original source... Go to PubMed...
  14. Iosifescu DV, Nierenberg AA, Albert JE et al. The impact of medical comorbidity on acute treatment in major depressive disorder. Am J Psychiatry, 160, 2003, 2122-2127. Go to original source... Go to PubMed...
  15. Jain R, Jackson CW, Gardner NC, Maletic V. Managing bipolar disorder from urgent situations to maintenance therapy, part 2: focus on maintenance. J Clin Psychiatry, 2007; 68: 1290-1300. Go to original source... Go to PubMed...
  16. Lieberman JA, Tollefson G, Tohen M et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry, 2003; 160: 1396-404. Go to original source... Go to PubMed...
  17. Lieberman JA, Stroup TS, McEvoy J et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. Can J Psychiatry, 2005; 50: 901-908. Go to original source... Go to PubMed...
  18. Manji HK, Quiroz JA, Sporn J et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-depression. Biol Psychiatry, 2003; 53: 707-742. Go to original source... Go to PubMed...
  19. Mayberg HS. Defining the neural circuitry of depression: toward a new nosology with therapeutic implications. Biol Psychiatry, 2007; 61: 729-730. Go to original source... Go to PubMed...
  20. Meyer JH, mcNeela HE, Sagrati S et al. Elevated putamen D(2) receptor binding potential in major depression with motor retardation. An (11) raclopride positron emission tomography study. Am J Psychiatry, 2006; 163: 1594-602. Go to original source... Go to PubMed...
  21. Meltzer HY. Suicide and schizophrenia: clozapine and the InterSePT study. J Clin Psychiatry, 1999; 60 (suppl 12): 47-50.
  22. Mort JR, Aparasu RR, Baer RK. Interaction between selective serotonin reuptake inhibitors and nonsteroidal antiinflammatory drugs: review of the literature. Pharmacotherapy, 2006; 25: 1307-1313. Go to original source... Go to PubMed...
  23. Nierenberg AA, DeCecco BA. Definitions of antidepressant treatment response, remission, nonresponse, partial response and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry, 2001; 61(suppl 16): 5-9.
  24. Perlis RH, Ostachem MJ, Patel JK et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEPBD). Am J Psychiatry, 2006; 163: 217-224. Go to original source... Go to PubMed...
  25. Rahimi R, Nikfar S, Abdollahi M. Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a meta-analysis of clinical trials. Reprod Toxicko, 2006; 22: 571-575. Go to original source... Go to PubMed...
  26. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 1999; 56: 241-247. Go to original source... Go to PubMed...
  27. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry, 2003; 160: 284-289. Go to original source... Go to PubMed...




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.